This startup develops diagnostic tools that use AI to analyze medical images and patient data, providing clinicians with insights into cancer aggressivity. Their platform helps personalize cancer treatment plans by estimating tumor behavior and guiding patient-specific therapeutic decisions.
Funding
Funding not disclosed
Founders
Product
Problem
Head and neck squamous cell carcinoma (HNSCC) affects nearly one million new individuals annually and has a 50% mortality rate, with little improvement in survival over recent decades. Current diagnostic methods lack the ability to accurately identify the most aggressive, life-threatening cases at the time of diagnosis.
Solution
Thestra provides diagnostic solutions that enable clinicians to estimate cancer aggressivity at the time of diagnosis and select the most effective therapies. Their patented EPLINEx™ solution uses artificial intelligence to analyze HNSCC tissue samples, identifying cases that are likely to be life-threatening. By identifying patients with aggressive cancers, clinicians can make more informed decisions about treatment options, potentially reducing side effects and improving patient outcomes.
Target Audience
The primary customers are clinicians and hospitals specializing in head and neck cancer treatment, seeking novel tools for accurate diagnosis and prognosis to facilitate decision-making and achieve cost savings.
Features
- Patented EPLINEx™ solution for identifying life-threatening HNSCC cases
- AI-based tissue analysis for diagnosis and prognosis
- Identification of HNSCC cases that are life threatening